1. Corvus Pharmaceuticals Soars on Goldman Sachs 'Buy' Rating for Lead Cancer Drug
Corvus Pharmaceuticals (CRVS) stock surged in pre-market trading following a significant vote of confidence from Wall Street giant Goldman Sachs. The investment bank initiated coverage of the biotech firm with a 'Buy' rating, specifically highlighting the potential of its lead clinical-stage asset, CPI-006. This analys...